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Abstract
The cellular metabolism of a living organism is among the most complex
systems that man is currently trying to understand. Part of it is described
by so-called protein-protein interaction (PPI) networks, and much effort is
spent on analyzing these networks. Recently, there has been much inter-
est in predicting involvement of network nodes (in this case, proteins) in
different diseases. Many approaches to this problem exist. We categorize
the previous studies into Individual and Network approaches. While the
Individual approach focuses on one specific disease without considering its
relationship with other diseases, the Network approach considers also these
relationships. In this paper, we construct a Human Disease Network (HDN),
using a novel approach for discovering relationships among different diseases.
We built the HDN for 20 different diseases based on functional and struc-
tural information available in the PPI network. We showed that the proposed
HDN is biologically meaningful and is capable of augmenting the initial prior
knowledge of different diseases by sharing information across highly-related
diseases. Furthermore, comparing to previous Individual and Network ap-
proaches, our proposed HDN increases the accuracy of predictive models and
discovers more and still informative relationships among different diseases,
respectively.
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1. Introduction
In recent years, much effort has been invested in the construction of
protein-protein interaction (PPI) networks [1]. Much can be learned from the
analysis of such networks with respect to the metabolic and signalling pro-
cesses present in an organism, and the knowledge gained can also be prospec-
tively employed e.g., for the task of protein function prediction [2, 3, 4], iden-
tification of functional modules [5], interaction prediction [6, 7], identification
of disease candidate genes [8, 9, 10, 11, 12, 13, 14, 15, 16, 17] and drug targets
[18, 19], according to an analysis of the resulting network [20].
Wu et al. [16] present an excellent overview of multiple methods for
detecting proteins involved in disease or cancer. Among the different methods
discussed in [16], “guilt-by-proximity” methods are well known. Methods
classified in this category are based on the assumption that genes that directly
interact, or, more generally, lie close to each other in the network, are more
likely to be involved in the same diseases (as argued by, e.g., Gandhi et
al. [21]). The methods vary based on how they define proximity: Some
methods consider only direct neighbors to be in the proximity (e.g., [15, 22]),
some quantify proximity of two proteins using the length of the shortest-path
between them, some compute a “Global Distance Measure” that also takes
into account how many paths there are between the two proteins, and how
long these are; an example is the approach by Chen et al. [23], who use a
PageRank based model for this.
The methods discussed by Wu et al. [16] mostly rely on notions of prox-
imity (to genes known to be disease-related) from the area of graph analysis.
An entirely different type of approaches are those that rely on feature-based
descriptions [17, 24, 25, 26]. There, each individual protein is described by
means of a fixed set of features. Next, using machine learning methods, a
model is learned that links some of these features to disease-relatedness.
In addition to methods which analyze each disease individually (Indi-
vidual Approach), other work has considered also the relationships among
human diseases (Network Approach) [27, 28, 29, 30, 31, 32]. Among these
network based approaches, Goh et al.’s method [27] has a prominent role.
This method connects two diseases in the network if there is at least one gene
that is implicated in both. However, their approach is not capable of dis-
covering relationships among diseases with no common disease-related genes.
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In this paper, we use contextual information from PPI networks (Structural
and Functional information), which is shown informative by previous studies
[33, 34], as one possible way of solving the limitations of Goh et al.’s method.
In the resulting network, two diseases even with no common disease-related
genes may be connected to each other if they are found to be similar with re-
spect to contextual information extracted from PPI networks. Our proposed
network improves Goh et al.’s method with respect to coverage (more rela-
tionships among diseases) and accuracy. Once the Human Disease Network
(HDN) is constructed, the information in the HDN can be used to obtain
new predictions, identifying genes that may be involved in some disease but
would not be detected using previous Individual and Network approaches.
We describe the proposed method in detail in Section 2. In Section 3,
the method is applied to a concrete PPI network; using functional and struc-
tural information from the network, a disease network is constructed for
20 diseases. This network is next evaluated in terms of interpretability and
knowledge augmentation, and compared to a disease network constructed us-
ing previous methods. Section 4 presents a case study, where the predictions
for one particular disease are analyzed and interpreted in detail. Section 5
concludes.
2. Methods
2.1. Terminology and Symbols
We consider a PPI network as an undirected annotated graph (P,E, λF , λD)
where P is a set of proteins, E ⊆ P ×P is a set of interactions between these
proteins, and λF and λD are so-called annotation functions; for each protein
p, λF and λD denote additional information we have about p. λF (p) lists all
the GO functions that are associated with p; we call it the function set (or
function vector) of p, and denote it FS(p). λD(p) lists all the diseases that
protein p is known to be involved in; we call it the disease list of p and denote
it dizList(p). If D = {d1, d2, . . . , dm} is the list of m analyzed diseases in
our paper, then dizListi(p) = 1 if p is involved in di and 0 otherwise. We
also define seed proteins SP (di) as the set of proteins involved in disease di
(di ∈ dizList(p)⇔ p ∈ SP (di)).
2.2. Human Disease Network
We define a Human Disease Network (HDN) as a directed graphHDN(D,R)
where D is a set of diseases and R ⊆ D×D is a set of directed relationships
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between these diseases. We build our proposed HDN as follows.
For each disease di, we learn a model that can predict, for any protein
p, how likely p is involved in this disease. Next, we use this model to make
predictions for all the seed proteins of a disease dj. The higher these seed pro-
teins score, on average, the stronger the link between di and dj is considered
to be.
Concretely, the model for a disease di is learned and used as follows:
1. let testSet contain the seed proteins of all diseases except di.
2. let trainSet contain all proteins not in testSet
3. We learn a predictive model M from trainSet, using the seed proteins
of di as positive examples and all other proteins as negative examples.
We then use M to predict for each protein in testSet how likely it is
involved in di (higher values meaning more likely). For randomized
learners, we repeat this 10 times (otherwise just 1 time) and calculate
for each p ∈ testSet the average, denoted APV (p).
4. For each disease dj ∈ D(j 6= i), we add a directed edge di → dj to the
HDN with a weight
weight(di → dj) =
∑
p∈SP (dj) APV (p)
|SP (dj)| (1)
with |SP (dj)| the number of seed proteins of dj.
This procedure is repeated for all diseases. The resulting HDN is a di-
rected, fully connected network in which each node is a disease and each
weighted edge shows a relationship between two diseases. A high weight for
di → dj expresses that proteins involved in dj are, on average, likely to be
involved also in di, according to the model built for di.
In order to focus on the most important relationships in the HDN, we
prune the network by keeping only the highest-ranked edges.
There are many ways in which the predictive model M can be learned
from the PPI network (step 3). In the following section, we discuss those
that we have experimented with.
2.3. Prediction Methods
Many methods for predicting which proteins are involved in certain dis-
eases have been proposed. We here distinguish three types: methods that use
the structural information in the PPI network, methods that use functional
information, and hybrid methods (which use both).
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2.3.1. Structural Category: Random Walk based Method (ST-RW)
Berger et al. [34] assume that disease-related proteins fall closer on aver-
age to the seed proteins than they do on average to the rest of the network.
They calculate the score of each protein pj in the network based on Formula
2 and then, select high-scoring proteins as disease-related proteins.
scores(pj) =
∑
i∈C′ Tij
|C′| −
∑
i∈C Tij
|C|∑
i Tij
|C|+|C′|
(2)
In Formula 2, Tij is the average number of steps a random walker takes
to walk from a specified node i to another specified node j, C is the set of
seed proteins and C ′ is the set of all other proteins in the network. In the
rest of this paper, we refer to this method as ST-RW.
2.3.2. Structural Category: ANOVA based Method (ST-Anova)
Rahmani et al. [3] proposed a relevance measure for proteins that is
inspired by analysis of variance (ANOVA), and showed that shortest-path
distance to a relatively small number of proteins (selected according to the
ANOVA-based measure) is informative for the task of function prediction in
the PPI network. Since this method works well for function prediction, we
consider it also for the task of predicting which proteins are involved in some
disease.
Let D be the set of proteins labeled with disease diz, and D¯ the set of
proteins not labeled with it. Given a particular protein q, if proteins inD tend
to have a shortest-path-distance to q that is very different from proteins in
D¯, then “shortest-path-distance to q” is an informative feature. We call this
feature δq. How informative δq is, can be measured using standard analysis
of variance. Let ES(δq) and V arS(δq) denote the sample mean and variance
of δq in a set S, respectively; then
Aq =
(ED(δq)− ED¯(δq))2
V arD(δq) + V arD¯(δq)
(3)
indicates to what extent the shortest-path-distance to q correlates with being
in D. A high Aq means that δq varies little within groups and/or much
between groups, which indicates that δq has high predictive power for the
group (i.e., for whether the protein is involved in the disease or not). Features
δq can be ranked according to Aq, and the top-k features selected as actual
features to be included in the description of all proteins.
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A standard machine learning system can next be used to learn a model
that from these informative features predicts the likelihood of involvement.
We here use Naive Bayes [35]. This method estimates the conditional prob-
ability distribution for the variable to be predicted, given the feature values,
and up to a constant factor, as follows:
p(C|F1, . . . , Fn) ∼ p(C)p(F1|C)p(F2|C) · · · p(Fn|C) (4)
This estimation of the conditional probability distribution relies on condi-
tional independence of the features given the target. This assumption is
usually violated, but the method is quite robust to violations of the assump-
tion [36], and works well in practice. Furthermore, several researchers found,
in a similar context, that the features are more important than the actual
machine learning method used [26].
The method of first selecting δq features using ANOVA, then applying
Naive Bayes to obtain the predictive model, is henceforth referred to as ST-
Anova.
2.3.3. Functional Category: Individual based Method (Func-Indiv)
This method uses the functional annotations of proteins. For each func-
tion, it determines how strongly the function correlates with disease-relatedness,
using the standard χ2 statistic as proposed by Liu et al. [37]:
χ2(fi) =
(ad− bc)2 ∗ (a+ b+ c+ d)
(a+ b)(c+ d)(b+ d)(a+ c)
(5)
where a = |D ∩Pi|, b = |D ∩ P¯i|, c = |D¯ ∩Pi|, and d = |D¯ ∩ P¯i|, with Pi and
P¯i the set of proteins labeled and not labeled with function fi, and D and D¯
the set of disease-related and not disease-related proteins, respectively.
Next, it describes all proteins using the highest-scoring functions as fea-
tures, and applies Naive Bayes to obtain a predictive model that uses these
features as input. In the rest of this paper, we refer to this method as Func-
Indiv.
2.3.4. Functional Category: Collaboration based Method (Func-Collab)
Selecting individual discriminative functions based on χ2(fi) does not
consider the network topology and the way different functions interact with
each other in the network. Rahmani et al. [38] showed that for the task of
predicting cancer-related proteins, it is possible that a function fi does not
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correlate itself with cancer-involvement, but interaction of the same function
with some function fj does correlate with the former protein being involved
in a cancer. Rahmani et al. [38] proposed a new way of calculating the χ2
of the function pairs in the PPI network.
They select high-ranked collaborative function pairs and then, they de-
scribe the proteins based on the high-ranked function pairs. In the end,
they applied the naive Bayes classifier for predicting the proteins involved in
cancer. In the rest of this paper, we refer to this method as Func-Collab.
2.3.5. Hybrid Category: Integrating Functional and Structural Information
Structural-based and functional-based methods can be simply combined
into hybrid methods as follows:
Hyb(p) = norm(ST (p)) + norm(Func(p)) (6)
where ST (p) and Func(p) represent the disease-relatedness score of p using
a Structural (ST-RW or ST-Anova) and a Functional (Func-Indiv or Func-
Collab) method, respectively. In order to avoid that one category dominates,
we normalize the disease-relatedness scores using
norm(xi) =
xi −min(x)
max(x)−min(x) (7)
where min(x) and max(x) return the minimum and maximum values taken
over all values of x, respectively.
Combining any structural method with any functional method gives four
hybrid methods, as shown in Table 1.
3. Empirical Results and Discussion
In this section, we discuss several aspects of the proposed method in more
detail, and investigate them experimentally.
The dataset used for the experiment is described in Section 3.1.
Recall that our method relies on a predictive model M , constructed using
one of the methods listed in Section 2.3. As the quality of the constructed
HDN is likely to depend on the quality of this model, in Section 3.2 we try
to determine experimentally which method is most reliable.
In Section 3.3, we show the HDN constructed by our method, and provide
a biological interpretation; this is meant as an evaluation of how informative
and interpretable the network is.
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Our method constructs the HDN from predictions about involvement in
a disease, rather than from confirmed data (the “seed proteins”). One may
wonder whether constructing the HDN using only the confirmed data would
work better. In fact, this procedure would correspond to the method pro-
posed earlier by Goh et al. [27]. In Section 3.4, we briefly discuss earlier
proposals for constructing human disease networks and experimentally com-
pare our HDN to Goh et al.’s.
Finally, a more objective type of evaluation is: how useful is the HDN
from the point of view of predicting involvement in diseases? Does using
the network yield better predictions? In section 3.5, we augment the initial
seed proteins of different diseases by sharing information across highly-related
diseases. Then, we evaluate the use of augmented seed proteins for predicting
disease-related proteins in two different ways.
3.1. Dataset
We applied our method for building the HDN to the PPI network used
by Milenkovic et al. [24]. This dataset is the union of three human PPI
datasets: HPRD [39], BIOGRID [40] and the dataset used by Radivojac et
al. [41] and contains 47, 303 physical interactions among 10, 282 proteins.
When we say “union”, we mean that the new network contains all the nodes
and edges (proteins and interactions) found in either of these networks. The
aim of merging these three datasets was to obtain as complete a human PPI
network as possible, i.e., a network that covers with its edges as many proteins
in the human proteome as possible. Milenkovic et al. [24] provide details on
the construction of the integrated network. The GO functions of proteins are
extracted from [42]. Table 2 shows some basic statistical information about
our annotated dataset.
Table 3 shows the list of 20 different diseases analyzed in Aerts et al.,
[43], in addition to their “Seed Count” and “Augmented Seed Count”. Seed
Count is the number of proteins initially listed as involved in the disease.
Augmented Seed Count is the number of proteins listed as involved after
applying our method, as discussed in detail in section 3.5.
3.2. Choosing a Prediction Method
Section 2.3 mentions a list of methods that could be used for building
a predictive model used to construct the HDN. We have experimentally de-
termined which of these methods gives the most reliable predictive model
on our dataset. The methods from Section 2.3 rely on a feature selection
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step, for which a number of features needs to be decided. Based on earlier
work on the same dataset [33], we consistently choose 100 functional and 10
structural features. Having made this choice, we compare the methods using
the following leave-one-out cross-validation procedure, proposed earlier by
De Bie et al. [44].
For each disease di:
1. Randomly select 99 proteins that are not seed proteins for di
2. For each seed protein p of di:
(a) let testSet contain p and the 99 proteins
(b) let trainSet contain all other proteins
(c) Learn a model M from trainSet, apply it to testSet, and check
how high p ranks.
3. Repeat steps 1 to 2 ten times and calculate the average rank AR(p) of
each seed protein p.
The overall rank of di, for a given method, is then defined as
overallRank(di) =
∑
p∈SP (di) AR(p)
|SP (di)| (8)
Among all the methods evaluated, RW-Indiv turns out best, so we selected
this prediction method for constructing the HDN. This outcome of evaluation
is based on the following analysis:
• Figure 1 compares the discussed prediction methods for the 20 different
diseases shown in Table 3 with respect to the diseases’ overall rank.
RW-Indiv achieves the best overall performance, compared to the other
methods.
• For each discussed method M , Table 4 shows the set of diseases for
which M produces the best result. Func-Indiv and RW-Indiv have the
largest sets.
• If we comapre the two best candidate methods Func-Indiv and RW-
Indiv to each other according to Figure 1, we conclude that when Func-
Indiv scores best (e.g., D-6, D-11 and D-19), it is only slightly better
than the second-best method; where it is not best, the difference with
the best method can be large (e.g., D-3, D-7, D-15, D-16). RW-Indiv,
on the other hand, never differs much with the best method.
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Note that these results are in line with the often observed fact that inte-
grating multiple types of data gives better predictive performance than using
one type of data.
3.3. Novel Human Disease Network
Using the RW-Indiv prediction method, we have built an HDN for the
20 diseases shown in Table 3. There are 380(20 × 19) possible edges in the
original HDN. Figure 2 shows the score distribution of 380 edges. The X
axis shows the 380 edges in the HDN and the Y axis shows the average
rank of seed nodes (the smaller, the better). There are two turning points
in the curve, roughly at 10% and 90% of all edges. Instead of analyzing the
whole HDN, we focus on the pruned HDN containing only the 38 (10% of
the original HDN) lowest-weighted edges. Figure 3 shows the pruned HDN
in addition to 4 clusters with Graph Density > 0.66. We should emphasize
that in our pruned Human Disease Network, each edge shows an informa-
tive relationship between two diseases and accordingly, the clustering method
should focus on network connections as main indicators of related diseases.
We choose the connectivity-based clustering approach using Graph Density,
discussed in Schaeffer, 2008 [45] to discover highly-related diseases in the
pruned network. The Graph Density of a cluster with N nodes is the ratio of
the number of edges E to the number of possible edges, ( E
N∗(N−1)). Compared
to other clustering approaches, connectivity-based clustering approaches con-
sider network connections as a main feature in a clustering process, they can
be used to filter out noise (outliers), they can discover clusters of arbitrary
shape and finally, there is no need to determine the (optimum) number of
clusters in advance [46].
For each edge (di)
rank−−→ (dj), Figure 3 shows the rank of the relationship
between two diseases di and dj among all the 380 disease pairs. The highest-
ranking found relationship is (deafness)
1−→ (usher syndrome).
We will now briefly discuss the biological significance of the observed find-
ings. The highest ranked connection (1.) between deafness and Usher’s Syn-
drome is apparent, given the latter is an inherited form of deafness. The link
between Deafness and Ehlers-Danlos syndrome however may be attributed
also to misdiagnosis of joint laxity, given that the combination of this observa-
tion with deafness is more likely to be correctly classified as Stickler syndrome
[47]. Epilepsy and Dystonia are both characterized by seizures, and given the
proximity of both terms in the Figure also a mechanistic connection between
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both disorders can be elucidated. Interesting is the relationship of Long QT
Syndrome (LQTS) to both Dystonia and Epilepsy, which hints at the im-
portance of ion channels being important in all of those cases. On the other
hand, Anyotrophic Lateral Sclerosis (ALS) is more related to Parkinson’s
disease (but neither epilepsy nor dystonia), hinting at fundamentally differ-
ent mechanisms behind those, on the surface similar, disorders characterized
by seizures. Apart from this seizure-cluster, also various cancer variations
are found to be closely related, namely Xeroderma Pigmentosum (leading
to sensitivity to UV light), breast cancer, lymphomas and colorectal cancer.
What is interesting is the close link of ALS with the cluster of cancers, since
indeed it is assumed that ALS, as a motor neuron disease, may represent a
particular case of paraneoplastic encephalomyelitis [48].
3.4. Comparison With Previous Methods
Several studies have focused on the modular nature of human diseases
[27, 28, 31, 32]. Goh et al. [27] propose a simple method for building an
undirected Human Disease Network. They connect two diseases di and dj in
the network if there is at least one gene that is implicated in both. Van Driel
et al. [28] calculate phenotype similarities among different disease by apply-
ing a text mining approach to the OMIM phenotype records using Medical
Subject Headings (MeSH) terms. Linghu et al. [31] construct a gene func-
tional network by combining multiple genomic data sources. Then, they use
the functional-linkage network to discover hidden associations between dis-
ease pairs having dissimilar phenotypes. More recently, Zhang et al. [32]
propose a method much in the same way as Goh et al. [27] that focuses on
rare, or orphan, disorders . They call the resulting network “Orphan Disease
Network” (ODN).
Complementary to molecular and genetic methods, Hidalgo et al. [49]
proposes a Phenotypic Disease Network (PDN) using phenotypic informa-
tion for human namely, patient clinical histories. In their PDN, nodes are
disease phenotypes and edges connect phenotypes that show significant co-
morbidity. They use Relative Risk [50] and Pearson’s correlation to quantify
the comorbidities among diseases. In the end, they conclude that the struc-
ture of the PDN is relevant to the understanding of disease evolution of
patients.
Considering the input information, our proposed method is extensible
with respect to considering the information used by the discussed approaches.
However Goh et al.’s method [27] is the only one that uses the same input
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information as our current input data, and as such is the most natural one to
compare to. The main drawback of Goh et al.’s method is in its incapability
of discovering relationships among diseases with no common disease-related
genes. Our method can be seen as one possible way of solving the limitations
of this method. For the comparison, we have applied Goh et al.’s method
to our disease dataset, and the resulting HDN is shown on Figure 4. For
each edge (di) ↔ (dj), Figure 4 shows the number of proteins involved in
both diseases di and dj (|SP (di) ∩ SP (dj)|). The best found relationship is
(anemia) ↔ (hemolytic anemia). Comparing our proposed HDN (Figure
3) with the disease network discussed by Goh et al. [27] (Figure 4), we
observe that our HDN is more informative than the network proposed by
Goh et al. [27]: it identifies more relationships between diseases. Obviously,
the quality of these relationships still needs to be evaluated; that is done
in the next section. Note that, since our method ranks the edges, one can
choose to include more or fewer edges in the network as desired; here, we
will simply evaluate the HDN obtained with our initial choice of selecting
the 10% highest-ranking edges.
3.5. Prediction from Augmented Seed Proteins
We now consider the task of predicting the involvement of proteins in
some disease, using a predictive model learned from data. The quality of
such a predictive model obviously depends on the prior knowledge incorpo-
rated in the data. While earlier models focused on knowledge about one
disease, we hypothesize that augmenting the prior knowledge about one dis-
ease with knowledge obtained from studying related diseases may yield better
predictive models.
To evaluate this hypothesis, we have used our proposed HDN for aug-
menting the seed proteins of different diseases as follows.
First, we clustered the pruned HDN into n clusters C1 . . . Cn based on the
network connectivity. This gave four clusters, shown in Figure 3. Second,
we augmented the seed proteins of each disease by adding the seed proteins
of all the diseases in the same cluster Cj; that is, di ∈ Cj ⇒ Aug(di) =
∪dk∈CjSP (dk), with Aug(di) the augmented list of seed proteins of disease
di. The augmented seed count of each disease is shown in the fourth column
of Table 3.
Next, we have evaluated the effect of using the augmented list to learn a
model, instead of the original list, along two dimensions: predictive accuracy,
as well as biological meaningfulness.
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First, we compare the predictions of a model learned using augmented
seed proteins (Network approach) with those of a model learned using only
the initial seed proteins (Individual approach). In both cases, the same
learning method was used (RW-Indiv).
Figure 5 compares the Network approach with the Individual approach
for 12 different diseases augmented by our HDN, in terms of the leave-one-
out cross validation ranking discussed in section 3.2. The Network approach
does not consistently outperform the Individual approach, but can perform
much better in individual cases, and does slightly better on average. This
suggests that it should not be seen as replacing the Individual approach, but
as complementary to it.
Beside the numerical evaluation mentioned above, we also want to eval-
uate to what extent the proposed network approach predicts biologically
meaningful results. To this aim, we try to find literature evidence for pro-
teins predicted to be involved in diseases even when they were not annotated
as such in the training data. Our approach consists of the following steps:
First, we build a new training set containing the augmented list of seed pro-
teins (positive set) in addition to 100 randomly selected proteins (negative
set). Even though we are not sure that all of these random proteins are neg-
ative, it is very likely that the majority of them are negative. The remaining
positive cases constitute noise in the training set. Second, we build a test
set containing all the remaining proteins in the network. Third, we use RW-
Indiv for predicting new proteins involved in the disease. Tables 5, 6, 7 and
8 show for each of the four clusters shown in Figure 3 the 10 highest-ranked
proteins predicted for each cluster.
The first cluster, covering Alzheimer and Ehler-Danlos syndrome, covers
both known and potential novel protein targets to treat those diseases. In
case of Alzheimer’s, BACE2, HSD17B10 and TM2D1 have been implicated in
literature before, while COL5A3, which encodes one of the fibrillar collagens,
has been established to be involved in Ehler-Danlos syndrome. On the other
hand, genes (and proteins) not explicitly associated with those diseases are
TGBF2, THBS1 and SPON1, all of which are known to be involved in cell-to-
cell interactions, cell-to-matrix interactions, and cell adhesion, respectively.
In particular SPON1 can readily be understood to be of importance, given
its involvement of attachment of neuron cells and neurite outgrowth.
Similar results covering both established and novel genes are observed for
the second cluster, with LQTS, Epilepsy and Dystonia. Dopamine levels and
epilepsy have been linked for a long time (DRD1, DRD3 and DRD4; [51]
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Dystonia) and they are of practical relevance for treatment. The KCNQ4
ion channel on the other hand has been previously linked with Long QT
Syndrom (LQTS). What is interesting, with potential practical implications,
is the importance of ALG10 in this cluster, which gates rat ether-a-go-go
(the human homolog of the hERG channel involved in LQTS) and which
might hence also play an important role in human. No explicit involvement
of the EPM2AIP1 gene, encoding laforin, has been described in literature
yet; however, our analysis makes a rather strong disease implication for the
three diseases present in this cluster.
The third cluster of neoplastic diseases, covering Xeroderma pigmento-
sum, breast cancer, lymphoma and colorectal cancer gives relatively little
surprises, with agreement on MSH3 and MSH6 which are both involved in
DNA repair, on the APC tumor suppressor protein, and the RELA oncogene
(which bings to the NF kappa b transcription factor with known involvement
in cancerogenesis).
The fourth and final disease cluster, of Zellweger syndrome, ALS, and
Usher’s Syndrome, involves the myosins MYO6, MYO3A and MYO15A
which are all known to be involved either in hearing loss or, in the latter case,
the actin organization in the hair cells of the cochlea. What is apparent is the
link of this set of disorders to the peroxisome, which has been established for
this disease cluster before (the involvement of PEX7 and PEX12 which are
involved in the assembly of peroxisomes is characteristic, but also ABCD1 is
involved in fatty acid transport into the peroxisome, and PXMP3 is involved
in its biogenesis). The potentially most surprising gene located in this dis-
ease cluster is SIRT3, which is known to be involved in epigenetic silencing
and which has been characterized as a potential antineoplastic target - given
its prominent role in this analysis, it might hence also play a role for drug
treatments of this set of diseases in the future.
Note that our method identifies a particular kind of relationship among
diseases that is based on correlations, and there is no guarantee that the
newly found gene-disease relationships are causal. Actual causality should
be determined experimentally, but the results from the HDN-based analysis
can be used to prioritize such experiments. The leave-one-out cross-validation
results discussed earlier confirm that the proposed HDN is valuable for such
prioritization.
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4. Case Study: Long QT Syndrome
In this section, we examine Long QT Syndrome (LQTS) in more detail.
According to [52], LQTS is a disorder of the heart’s electrical activity which
can cause sudden, uncontrollable, dangerous arrhythmias in response to ex-
ercise or stress. Table 9 shows the set of proteins involved in LQTS.
4.1. Most Relevant Features for Long QT Syndrome
The number of different functions occurring in our human dataset is 9833;
this is also the dimensionality of the Func-Indiv method if no dimensionality
reduction is used. As we discussed in section 2.3.3, we can use a χ2-based
feature selection methods to reduce this number; at the same time, this
technique ranks functions according to how relevant they are for prediction
of disease relatedness.
Table 10 shows the ten most discriminant individual functions obtained.
It can be seen that the top three GO annotations are explicitly related to
cardiac action potential (regulation of heart contraction, regulation of ven-
tricular cardiomyocyte membrane repolarization and negative regulation of
sarcomere organization). Positions 4 and 5 are concerning caveolar signaling
(which is also very prominent in the heart) and regulation of skeletal muscle
contraction, alluding to the fact that muscle contraction in the skeleton and
in the heart is goverened by related processes. Membrane rafts (as well as
caveolae) are important for cardiac ion channel function as has been found
before, [53] which is also correctly identified in Table 10. T-tubule organiza-
tion, while not immediately apparent, has been linked to a ’new paradigm’
for human arrhythmias recently [54]. It is interesting that explicit potassium
and ion channel activity are appearing only low in this list, along with the
broad term of blood circulation. Hence, overall it can be said that the most
discriminative functions are meaningful, with specific functions appearing at
the top, biologically derived functions (raft organization, T-tubule organiza-
tion) in the middle, and general terms at the bottom of the terms derived
from the analysis.
Our dataset contains 10,282 proteins. The Anova based method uses the
ANOVA measure to select the most relevant among these. This measure
has been applied also to the identification of differentially expressed genes in
microarray data [55]. More detailed information could be obtained from an
ANOVA analysis of the most relevant proteins among the full set of 10,282
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proteins. Table 11 now shows the ten proteins with the highest ANOVA mea-
sure obtained using our analysis. Interestingly, no ion channel has been most
signficiant, but the NADH dehydrogenase NDUFS6. It has been found that
HDUSF6 knockouts cause mitochondrial complex I deficieny [56], causing
various cardiac problems such as reduced systolic function and cardiac out-
put. On the one hand, this might relate to a functional relationship between
diseases; on the other hand it might indicate imperfect diagnosis, hence con-
fusing different underlying disease biology. The six Potassium channels listed
can be understood to be involved in direct polarization and depolarization of
the cardiac action potential; however the three remaining proteins, namely
AKAP6, ALG10B and KCR1 deserve particular attention here. AKAP6 (also
called mAKAP) anchors Protein Kinase A to RYR2 which is able to generate
Ca2+ ’sparks’ due to simultaneous activation within a certain neighborhood
radius [57], and hence importance to the cardiac action potential and devi-
ations thereof. ALG10B (also known as KCR1) is interestingly thought to
be able to reduce KCNH2 sensitivity to proarrhythmic drug blockade which
may be due to glycosylation of this potasssium channel [58, 59], hence our
method was able to not only identify protein directly involved in causing
LQTS, but also modifier proteins such as AKAP6 and ALG10B.
4.2. Predicting LQTS-Related Proteins using Initial Seed Proteins
In section 3.5, we have already discussed what proteins are predicted as
involved in LQTS by the Network based method (Table 6). We here make
the same exercise for LQTS using the Individual based approach; in the next
section, we will then compare both, illustrating the complementarity between
them.
Table 12 lists the highest ranked newly identified LQTS-related genes. In
agreement with expectations, many of the genes identified are (as hERG it-
self) voltage-gated Potassium channels; however also Sodium channels (SNC4A),
Calcium channels (CACNB3 and CACNA1A) and solute carriers (SLC8A1)
appear in the list. This is in agreement with the known proteins involved in
the regulation of cardiac action potential, which are known to involve all three
types of ions. KCNJ8 seems to be involved in cardiovascular sudden death at
least in mouse models [60], indicating that while focusing on LQTS is of high
practical relevance in today’s drug development environment, one can in turn
also assume that other ion channels involved in drug adverse reactions are
currently not receiving sufficient attention. SLC8A1, as a sodium/calcium
exchanger, is known to be involved in regulating action potential as well [61],
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though it is not easy to find a specific link to the QT interval prolongation in
this case. SCN4A mutations have been found to be insignificant under stan-
dard conditions, but become relevant in patients treated with LQ-inducing
drugs [62]. This finding is interesting since it appears also synergistic ad-
verse relations between genes and LQTS syndrome can be identified using
our network approach. One of the potassium channels newly identified to
be involved in cardiac action potential regulation (and, hence, with poten-
tial LQTS liability) is KCJN12 [63], which is indeed thought to be invovled
in providing the cardiac inward rectifier current (IK1). A similar observa-
tion can be made regarding KCNA1, where it is thought that a brain-driven
cardiac dysfunction can be made responsible for sudden death syndrome in
epilespy patients [64]. Mutations in CACNA1 are classified as ’LQTS8’ and,
while rare, have been shown to be linked to LQTS [65]. Hence, overall we
can find associations between the genes identified here and LQTS in many
cases - and, interestingly, often they are dependent on the particular genetic
or drug treatment conditions of the patients (such as in case of SCN4A and
KCNA1).
4.3. Individual vs. Network Based Predictions for LQTS
In this section, we compare the novel LQTS-related proteins predicted by
the Network approach and shown in Table 6 with the result of the Individual
approach shown in Table 12.
Considerable differences are apparent from the proteins included in the
cluster including LQTS along with Epilespy and Dystonia (Table 6), and the
prediction of LQTS-related proteins (Table 12). The receptors identified in
Table 6 are on the one hand G-Protein Coupled Receptors (GPCRs) such as
the Dopamine D1, D3 and D4 receptor subtypes identified with the highest
rank in the disease cluster. The only ion channel selected is KCNQ4, which
has been linked to deafness [66]; however, only related potassium channels
appear to have been linked to LQTS until this stage. On the other hand,
KCR1 (ALG10B), which is though to modulate sensitivity to drugs causing
LQTS, also appears in this list (as well as in Table 11, in the list of most
significant proteins according to ANOVA-based selection). On the other
hand, Table 12 is very much dominated by the different subtypes of voltage-
gated potassium channels, which occupy 6 out of the 10 positions when RW-
indiv is applied to the selection of novel proteins, with the remaining genes
selected being ion channels or exchangers of sodium and/or calcium ions.
Hence, it can be seen that both methods arrive at a very different selection
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of genes involved in the disease cluster, as well as the identification of novel
disease genes using the RW-Indiv method. Combined with the fact that very
disease relevant genes were identified in Table 12 (as discussed above), we
believe that this illustrates the performance of the method implemented in
this work.
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5. Conclusions and Future Work
The previous studies on analyzing different diseases can be categorized
into the Individual and Network approaches. While the Individual approach
focuses on one specific disease without considering its relationship with other
diseases, the Network approach considers also the diseases relationships.
In this paper, we have proposed, first, a method for building disease net-
works that considers both functional and structural information in a given
PPI network, and, second, a specific Human Disease Network (HDN) result-
ing from this method. To test the usefulness of this HDN, we have evaluated
it in terms of predictive accuracy and biological meaningfulness, and we have
compared it to a network constructed using previous methods.
Analyzing different functional and structural prediction methods, we ob-
served that a hybrid method that considers both functional and structural
information in the PPI network worked best for building the HDN. We built
an HDN for 20 different diseases, and showed that it is biologically meaning-
ful by finding evidence in the literature for the relationships discovered by
our method among different diseases. We compared our HDN with one con-
structed from the same dataset using a previous Network approach [27], and
we observed that our method is capable of discovering more (38 versus 8) and
still informative relationships among different diseases. In the last step of the
evaluation, we clustered the HDN nodes based on their connectivity and we
augmented the seed proteins of diseases based on the cluster they belong to.
Then, we compared the predictions of models learned using the augmented
list with those of models learned using the original list. We observed that
considering the relationships among different diseases worked slightly better
(9.43 versus 11.01 with respect to average rank of seed proteins) than ignor-
ing them, but, more importantly, it gave highly complementary results both
in terms of ranking accuracy and of biological interpretation.
As future work, we could improve and extend the proposed method in
several directions. In the first direction, we could apply more extensive val-
idation to the result of our proposed approach. We have already discussed
and validated our results in sections 3.3, 3.5 and 4 using literature mining,
however, biological/experimental validation of the findings using methods
such as PR and RT-PCR is still challenging and needs separate studies. Ad-
ditionally, although we believe strongly that the results of this paper reduce
the search space, generate novel hypothesis and bring new insights for the
biologists and clinical researchers, these results should not be assumed as ef-
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fective and employed in action by pharmaceutical companies unless they are
validated experimentally in the laboratories. In the second direction, in ad-
dition to functional and structural feature, we could consider other biological
features in the system. In the third direction, we could apply our method
to other genomics and metabolomics dataset. We have used the proposed
method to augment the initial drug-targets of 200 drugs and a text is being
prepared containing these results.
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6. Tables
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Table 1: List of the 4 different hybrid methods considering structural and functional
information in the network.
Structural Method Functional Method Hybrid Method
ST-RW Func-Indiv RW-Indiv
ST-RW Func-Collab RW-Collab
ST-Anova Func-Indiv Anova-Indiv
ST-Anova Func-Collab Anova-collab
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Table 2: Basic statistical information about our annotated dataset.
Number of Proteins 10,282
Min Degree 1
Max Degree 272
Average Degree 9.39
Number of Proteins with no Function 1519
Average Number of Functions for each Protein 10.40
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Table 3: List of the 20 different diseases analyzed in this paper.
Disease ID Disease Name Seed Count Augmented
Seed Count
D 1 Alzheimer 7 14
D 2 Amyotrophic 4 17
D 3 Anemia 36 36
D 4 Breast Cancer 21 72
D 5 Cataract 14 14
D 6 Charcot-marie-tooth 11 11
D 7 Colorectal-cancer 20 72
D 8 Deafness 28 28
D 9 Diabetes 23 23
D 10 Dystonia 5 29
D 11 Ehlers-danlos 7 14
D 12 Hemolytic-anemia 11 11
D 13 Epilepsy 11 29
D 14 Long QT Syndrome 13 29
D 15 Lymphoma 27 72
D 16 Mental-retardation 19 19
D 17 Parkinson 8 8
D 18 Usher-syndrome 5 17
D 19 Xeroderma 10 72
D 20 Zellweger 8 17
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Table 4: Set of diseases in which each method produces the best result.
Method M Set of diseases which M
produces the best results Count
ST-RW D 15, D 16 2
ST-Anova D 7 1
Func-Indiv D 2, D 5, D 6, D 8, D 11, D 13, D 19 7
Func-Collab D 18 1
RW-Indiv D 1, D 3, D 9, D 10, D 12, D 14, D 20 7
RW-Collab – 0
Anova-Indiv D 4, D 17 2
Anova-Collab – 0
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Table 5: 10 highest-ranked proteins predicted for cluster 1 = {Alzheimer, ehler-danlos}.
Index Protein Symbol Full Protein Name
1 COL5A3 Collagen, type V, alpha 3
2 THBS1 Thrombospondin 1
3 TGFB2 Transforming growth factor, beta 2
4 COL5A2 Collagen, type V, alpha 2
5 PDGFA Platelet-derived growth factor alpha polypeptide
6 SPON1 Spondin 1, extracellular matrix protein
7 HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10
8 HADH2 Hydroxysteroid (17-beta) dehydrogenase 10
9 BACE2 Beta-site APP-cleaving enzyme 2
10 TM2D1 TM2 domain containing 1
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Table 6: 10 highest-ranked proteins predicted for each cluster 2 = {LQTS, Epilepsy,
Dystonia}.
Index Protein Symbol Full protein Name
1 DRD4 Dopamine receptor D4
2 DRD3 Dopamine receptor D3
3 DRD1 Dopamine receptor D1
4 ALG10B Asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase
homolog B (yeast)
5 KCR1 A membrane Protein That Facilitates Functional Expression of
Non-inactivating K+ Currents Associates with Rat EAG
Voltage-dependent K+Channels
6 EPM2AIP1 EPM2A (laforin) interacting protein 1
7 KCNQ4 Potassium voltage-gated channel, KQT-like subfamily, member 4
8 TOR1B Torsin family 1, member B (torsin B)
9 HSPC163 –
10 GCHFR GTP cyclohydrolase I feedback regulator
34
Table 7: 10 highest-ranked proteins predicted for cluster 3 = {xeroderma-pigmentosum,
breast-cancer-leon, lymphoma, colorectal-cancer}.
Index Protein Symbol Protein Full Name
1 MSH6 MutS homolog 6 (E. coli)
2 MSH3 MutS homolog 3 (E. coli)
3 APC Adenomatous polyposis coli
4 RELA V-rel reticuloendotheliosis viral oncogene homolog A (avian)
5 TGFBR1 Ransforming growth factor, beta receptor 1
6 PTK2B PTK2B protein tyrosine kinase 2 beta
7 HIPK2 Homeodomain interacting protein kinase 2
8 RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1
9 TGFB1 Transforming growth factor, beta 1
10 ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian)
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Table 8: 10 highest-ranked proteins predicted for cluster 4 = {zellweger-syndrome,
amyotrophic-lateral-slecrosis, usher-syndrome}.
Index Protein Symbol Protein Full Name
1 MYO15A Myosin XVA
2 MYO3A Myosin IIIA
3 MYO6 Myosin VI
4 DDO D-aspartate oxidase
5 PEX12 Peroxisomal biogenesis factor 12
6 PEX7 Peroxisomal biogenesis factor 7
7 PXMP3 Peroxisomal membrane protein 3
8 SIRT3 Sirtuin 3
9 AGXT Alanine-glyoxylate aminotransferase
10 ABCD1 ATP-bindende cassette, sub-familie D (ALD), lid 1
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Table 9: Proteins associated with the Long QT Syndrome. The data is taken from Berger
et. al.[34].
Index Protein sybmbol Full Protein name
1 KCNQ1 Potassium voltage-gated channel, KQT-like subfamily, member 1
2 KCNH2 Potassium voltage-gated channel, subfamily H (eag-related),
member 2
3 SCN5A Sodium channel, voltage-gated, type V, alpha subunit
4 ANK2 Ankyrin 2, neurona l
5 KCNE1 Potassium voltage-gated channel, Isk-related family, member 1
6 KCNE2 Potassium voltage-gated channel, Isk-related family, member 2
7 KCNJ2 Potassium inwardly-rectifying channel, subfamily J, member 2
8 CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit
9 CAV3 Caveolin 3
10 SCN4B Sodium channel, voltage-gated, type IV, beta
11 AKAP9 A kinase (PRKA) anchor protein (yotiao) 9
12 SNTA1 Syntrophin, alpha 1
13 ALG10 Asparagine-linked glycosylation 10 homolog
(yeast, alpha-1,2-glucosyltransferase)
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Table 10: 10 most discriminative functions according to χ2(fi) (Formula 5).
Index Function Short Description
1 GO:0008016 Regulation of heart contraction
2 GO:0060307 Regulation of ventricular cardiomyocyte membrane repolarization
3 GO:0060299 Negative regulation of sarcomere organization
4 GO:0002095 Caveolar macromolecular signaling complex
5 GO:0014819 Regulation of skeletal muscle contraction
6 GO:0031579 Membrane raft organization
7 GO:0033292 T-tubule organization
8 GO:0005251 Delayed rectifier potassium channel activity
9 GO:0005244 Voltage-gated ion channel activity
10 GO:0008015 Blood circulation
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Table 11: 10 most discriminative proteins according to Anova (Formula 3).
Index Protein Short Description
1 NDUFS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial
2 KCNH1 Potassium voltage-gated channel subfamily H member 1
3 KCNH5 Potassium voltage-gated channel, subfamily H (eag-related), member 5
4 KCNF1 Potassium voltage-gated channel subfamily F member 1
5 AKAP6 A-kinase anchor protein 6
6 ALG10B Asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase
homolog B
7 KCR1 A membrane Protein That Facilitates Functional Expression of
Non-inactivating K+ Currents Associates with Rat EAG
Voltage-dependent K+Channels
8 KCNE1 Potassium voltage-gated channel subfamily E member 1
9 KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2
10 KCNE2 Potassium voltage-gated channel subfamily E member 2
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Table 12: Newly identified LQTS-related proteins by applying RW-Indiv method to the
original seed proteins.
index Gene-Name Short Description
1 KCNH1 Potassium voltage-gated channel, subfamily H (eag-related), member 1
2 KCNH5 Potassium voltage-gated channel, subfamily H (eag-related), member 5
3 KCNJ8 Potassium inwardly-rectifying channel, subfamily J, member 8
4 SLC8A1 Solute carrier family 8 (sodium/calcium exchanger), member 1
5 SCN4A Sodium channel, voltage-gated, type IV, alpha subunit
6 KCNJ4 Potassium inwardly-rectifying channel, subfamily J, member 4
7 CACNB3 Calcium channel, voltage-dependent, beta 3 subunit
8 KCNJ12 Potassium inwardly-rectifying channel, subfamily J, member 12
9 KCNA1 potassium voltage-gated channel, shaker-related subfamily,
member 1 (episodic ataxia with myokymia)
10 CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit
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7. Figures Captions
Figure 1: Average rank of seed proteins in 20 different diseases shown in
Table 3. RW-Indiv achieves the best overall performance comparing to the
other methods and is therefore a good candidate method for building the
HDN.
Figure 2: The score distribution of the 380 edges in HDN. The X axis
shows the 380 edges in the HDN and the Y axis shows the average rank of
seed nodes (the smaller, the better). There are two turning points x = 38
and x = 331 in this figure.
Figure 3: Pruned Human Disease Network by keeping only 38 (10% of
the original HDN) highest-ranked relationships among different diseases. In
this network, each node di is a disease and each edge (di)
rank−−→ (dj) is a rank
of the relationship between two diseases di and dj among all the 380 disease
pairs. The best found relationship is (deafness)
1−→ (usher syndrome).
We cluster the pruned HDN based on the network connectivity and the 4
discovered clusters are shown in grey squares in this figure. As it can be
seen, the different cancer types present in the dataset share the same cluster
(cluster #3), while other clusters (e.g. cluster #4) share diseases that are also
known to exhibit related phenotypes (such as Usher syndrome and Zellweger
syndrome, which are both frequently characterized by visual and hearing
impairments, among other effects).
Figure 4: Human Disease Network based on the common proteins (Pro-
posed by Goh et al. [27]). In this network, each node di is a disease and
each edge (di)↔ (dj) is the number of common proteins between two related
diseases.
Figure 5: Comparing the Network approach with the Individual approach
for 12 different diseases augmented by our HDN. For several diseases, the
Network based approach outperforms the Individual approach with respect
to ranking the seed proteins in a leave-one-out cross validation.
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8. Figures
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Figure 1: Average rank of seed proteins in 20 different diseases shown in Table 3. RW-Indiv
achieves the best overall performance comparing to the other methods and is therefore a
good candidate method for building the HDN.
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Figure 2: The score distribution of the 380 edges in HDN. The X axis shows the 380 edges
in the HDN and the Y axis shows the average rank of seed nodes (the smaller, the better).
There are two turning points x = 38 and x = 331 in this figure.
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Figure 3: Pruned Human Disease Network by keeping only 38 (10% of the original HDN)
highest-ranked relationships among different diseases. In this network, each node di is a
disease and each edge (di)
rank−−−→ (dj) is a rank of the relationship between two diseases
di and dj among all the 380 disease pairs. The best found relationship is (deafness)
1−→
(usher syndrome). We cluster the pruned HDN based on the network connectivity and
the 4 discovered clusters are shown in grey squares in this figure. As it can be seen, the
different cancer types present in the dataset share the same cluster (cluster #3), while
other clusters (e.g. cluster #4) share diseases that are also known to exhibit related
phenotypes (such as Usher syndrome and Zellweger syndrome, which are both frequently
characterized by visual and hearing impairments, among other effects).
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Figure 4: Human Disease Network based on the common proteins (Proposed by Goh et al.
[27]). In this network, each node di is a disease and each edge (di)↔ (dj) is the number
of common proteins between two related diseases.
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Figure 5: Comparing the Network approach with the Individual approach for 12 different
diseases augmented by our HDN. For several diseases, the Network based approach outper-
forms the Individual approach with respect to ranking the seed proteins in a leave-one-out
cross validation.
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